Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Registro de resultados prospectivos de fibrosis pulmonar idiopática y enfermedad pulmonar intersticial (IPF/ILD-PRO)

9 de noviembre de 2026 actualizado por: Duke University

Registro de resultados prospectivos de fibrosis pulmonar idiopática (IPF-PRO) y enfermedad pulmonar intersticial crónica fibrosante con resultados prospectivos de fenotipo progresivo (IPF-PRO/ILD-PRO)

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Tipo de estudio

De observación

Inscripción (Estimado)

3000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • Reclutamiento
        • University of Alabama - Birmingham
        • Investigador principal:
          • Tejaswini Kulkarni, MD
        • Contacto:
          • Arnissa Hopson
          • Número de teléfono: 205-934-1657
          • Correo electrónico: agoggins@uabmc.edu
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85721
        • Reclutamiento
        • University of Arizona
        • Investigador principal:
          • Sally A Suliman, MD
        • Contacto:
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • Reclutamiento
        • University of Southern California
        • Contacto:
        • Investigador principal:
          • Toby Maher, MD
      • Los Angeles, California, Estados Unidos, 90024
        • Reclutamiento
        • University of California - Los Angeles
        • Investigador principal:
          • John Belperio, MD
        • Contacto:
      • Stanford, California, Estados Unidos, 94305
        • Reclutamiento
        • Stanford University
        • Investigador principal:
          • Rishi Raj, MD
        • Contacto:
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Reclutamiento
        • University of Colorado
        • Investigador principal:
          • Joyce Lee, MD
        • Contacto:
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Reclutamiento
        • Yale University
        • Investigador principal:
          • Mridu Gulati, MD
        • Contacto:
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610-3175
        • Reclutamiento
        • University of Florida
        • Contacto:
        • Investigador principal:
          • Diana Gomez Manjarres, MD
      • Tampa, Florida, Estados Unidos, 33606
        • Reclutamiento
        • University of South Florida
        • Investigador principal:
          • Jose D Herazo-Maya, MD
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University
        • Contacto:
        • Investigador principal:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, Estados Unidos, 30106
        • Reclutamiento
        • Piedmont Healthcare
        • Investigador principal:
          • Amy Case, MD
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Reclutamiento
        • University of Chicago
        • Investigador principal:
          • Mary Strek, MD
        • Contacto:
      • Evanston, Illinois, Estados Unidos, 60611
        • Reclutamiento
        • Northwestern University
        • Contacto:
        • Investigador principal:
          • Bradford Bemiss, MD
      • Maywood, Illinois, Estados Unidos, 60153
        • Reclutamiento
        • Loyola University Health System
        • Investigador principal:
          • Daniel Dilling, MD
        • Contacto:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Terminado
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Reclutamiento
        • University of Kentucky
        • Investigador principal:
          • Girish Nair, MD
        • Contacto:
          • Kai Su
          • Número de teléfono: 859-257-4501
          • Correo electrónico: kai.su@uky.edu
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Reclutamiento
        • Tulane University
        • Investigador principal:
          • Joe Lasky, MD
        • Contacto:
          • Sandy Ditta
          • Número de teléfono: 504-988-4040
          • Correo electrónico: sditta@tulane.edu
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Activo, no reclutando
        • University of Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Reclutamiento
        • Henry Ford Health
        • Contacto:
          • Deepti Naidu
          • Número de teléfono: 313-916-8732
          • Correo electrónico: dnaidu1@HFHS.ORG
        • Investigador principal:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • Reclutamiento
        • University of Minnesota
        • Contacto:
          • Mandi DeGrote
          • Número de teléfono: 612-626-7609
          • Correo electrónico: carl1032@umn.edu
        • Investigador principal:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39216
        • Reclutamiento
        • University of Mississippi Medical Center
        • Investigador principal:
          • Kimberly Dobbs, MD
        • Contacto:
          • Leadeashia Brackett
          • Número de teléfono: 601-496-7814
          • Correo electrónico: lbrackett@umc.edu
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University
        • Investigador principal:
          • Tonya Russell, MD
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Weill Medical College of Cornell University
        • Investigador principal:
          • Kerri Aronson, MD
        • Contacto:
      • New York, New York, Estados Unidos, 10016
        • Activo, no reclutando
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • Reclutamiento
        • UNC Chapel Hill
        • Investigador principal:
          • Jason Lobo, MD
        • Contacto:
      • Durham, North Carolina, Estados Unidos, 27705
        • Reclutamiento
        • Duke University
        • Investigador principal:
          • Lake Morrison, MD
        • Contacto:
      • Greensboro, North Carolina, Estados Unidos, 27403
        • Reclutamiento
        • Pulmonix LLC
        • Investigador principal:
          • Murali Ramaswamy, MD
        • Contacto:
      • Wilmington, North Carolina, Estados Unidos, 28401
        • Terminado
        • PMG Research
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Reclutamiento
        • Wake Forest Baptist Health
        • Contacto:
        • Investigador principal:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45267
        • Activo, no reclutando
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Reclutamiento
        • Cleveland Clinic
        • Investigador principal:
          • Brian Southern, MD
        • Contacto:
          • Ron Wehrmann
          • Número de teléfono: 2164450574
          • Correo electrónico: wehrmar@ccf.org
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • The Ohio State University
        • Contacto:
        • Investigador principal:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Reclutamiento
        • University of Oklahoma
        • Investigador principal:
          • Jad Kebbe, MD
        • Contacto:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97220
        • Reclutamiento
        • Oregon Clinic
        • Investigador principal:
          • David Hotchkin, MD
        • Contacto:
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Reclutamiento
        • Penn State College of Medicine - Hershey
        • Investigador principal:
          • Rebecca Bascom, MD
        • Contacto:
      • Philadelphia, Pennsylvania, Estados Unidos, 19140
        • Reclutamiento
        • Temple University
        • Investigador principal:
          • Rachel Criner, MD
        • Contacto:
      • Philadelphia, Pennsylvania, Estados Unidos, 19144
        • Reclutamiento
        • Thomas Jefferson University
        • Investigador principal:
          • Ross Summer, MD
        • Contacto:
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Reclutamiento
        • Medical University of South Carolina
        • Investigador principal:
          • Timothy Whelan, MD
        • Contacto:
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University
        • Contacto:
        • Investigador principal:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
        • Reclutamiento
        • University of Texas Southwestern
        • Investigador principal:
          • John Fitzgerald, MD
        • Contacto:
      • Dallas, Texas, Estados Unidos, 75246
        • Reclutamiento
        • Baylor University Medical Center at Dallas
        • Investigador principal:
          • Yolanda Mageto, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Baylor College of Medicine
        • Investigador principal:
          • Ivan Rosas, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Houston Methodist Lung Center
        • Investigador principal:
          • Zeenat Safdar, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • The University of Texas Health Science Center At Houston
        • Investigador principal:
          • Rodeo Abrencillo, MD
        • Contacto:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • Reclutamiento
        • University of Utah
        • Contacto:
        • Investigador principal:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, Estados Unidos, 84111
        • Reclutamiento
        • Intermountain Health
        • Contacto:
        • Investigador principal:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, Estados Unidos, 05446
        • Activo, no reclutando
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Activo, no reclutando
        • University from Virginia
      • Falls Church, Virginia, Estados Unidos, 22042-3307
        • Reclutamiento
        • Inova Health Care Services
        • Contacto:
        • Investigador principal:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Activo, no reclutando
        • The Medical College of Wisconsin

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Descripción

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Data on management practices compared to existing guidelines.
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Periodo de tiempo: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de junio de 2014

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de enero de 2031

Fechas de registro del estudio

Enviado por primera vez

31 de julio de 2013

Primero enviado que cumplió con los criterios de control de calidad

1 de agosto de 2013

Publicado por primera vez (Estimado)

5 de agosto de 2013

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Pro00046131
  • 1199.174 (Otro identificador: DCRI)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .